PofoliaShared via Pofolia

BMC Pharmacology and Toxicology· 2026Q2

Ultrasound-responsive doxorubicin microbubbles engineered by QbD: enhanced in vitro anti-breast-cancer efficacy with attenuated cardiac cell toxicity

Sonal Solanki, Sreekanth Thota, Mahesh Kumar Posa, Shama Aphale et al.

Short summary

Ultrasound-responsive doxorubicin microbubbles engineered using Quality by Design (QbD) show enhanced in vitro anti-breast-cancer efficacy (IC₅₀ = 0.0013 µg/mL vs. 0.62 µg/mL for free doxorubicin) and significantly reduced cardiac cell toxicity (IC₅₀ ≈ 8.72 µg/mL without ultrasound).

AI-generated from the title and abstract; the full text is not read.

Key points

  • A Quality by Design (QbD) strategy was used to engineer doxorubicin-loaded microbubbles with controlled size (≈ 3.2 µm) and encapsulation efficiency (≈ 70–75%).
  • Ultrasound activation triggered rapid drug release (> 80% within 40 s) with minimal leakage under non-activated conditions.
  • Optimized microbubbles showed significantly enhanced in vitro efficacy against MCF-7 breast cancer cells (IC₅₀ = 0.0013 µg/mL) compared to free doxorubicin (IC₅₀ = 0.62 µg/mL).
  • Cardiac toxicity in H9c2 cells was attenuated (IC₅₀ ≈ 8.72 µg/mL), resulting in a >10³-fold improvement in therapeutic selectivity upon ultrasound activation.

AI-generated from the title and abstract; the full text is not read.

Abstract

Abstract Ultrasound-responsive microbubbles provide a powerful means for externally regulated drug delivery, yet their translation is often constrained by empirical formulation approaches and limited therapeutic selectivity. In this study, a Quality by Design (QbD) strategy was implemented to rationally engineer doxorubicin-loaded chitosan microbubbles with predictable physicochemical and biological performance. A Box–Behnken experimental design enabled systematic optimization of critical formulation variables, yielding a statistically validated design space governing microbubble size (≈ 3.2 µm), encapsulation efficiency (≈ 70–75%), and ultrasound-triggered burst release (> 80% within 40 s). The optimized formulation demonstrated minimal baseline drug leakage under non-activated conditions, while brief ultrasound exposure induced rapid, on-demand release. In vitro evaluation revealed a marked enhancement of anticancer efficacy in MCF-7 breast cancer cells following ultrasound activation, with a dramatic reduction in IC₅₀ to 0.0013 µg/mL compared with free doxorubicin (0.62 µg/mL). In contrast, cardiotoxicity in H9c2 cardiomyoblast cells remained attenuated under non-triggered conditions (IC₅₀ ≈ 8.72 µg/mL), resulting in a > 10³-fold improvement in therapeutic selectivity upon ultrasound activation. Mechanistic analysis indicated that intact microbubbles restrict passive drug diffusion, whereas ultrasound-induced cavitation and transient membrane permeabilization enable efficient intracellular delivery at the target site. Overall, this work demonstrates that integrating QbD-driven formulation control with spatially confined ultrasound activation can substantially expand the therapeutic window of doxorubicin, offering a transferable framework for precision, stimulus-responsive drug delivery without chemical modification of the parent drug.

The authors' abstract, as published at the source. BMC Pharmacology and Toxicology, 2026 · DOI ↗

TakeawaysPremium
Ask the paperFree account

Continue with a free account

Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.

Continue free on the web

Sign in with Google or Apple; no card needed. You come back to this paper.

On your phone:

Field: Biomedical Engineering

Biomedical EngineeringEngineering